STL Index for: antibiotic

Cystic acne is characterized by the formation of cysts enclosing a mixture of keratin and sebum in varying proportions. It is the most severe of the four main types of acne, which are comedonal, papular, pustular, and cystic. Identification and treatment options are discussed.

Recognition and appropriate treatment of these common bacterial skin infections, while at times challenging, can be very rewarding for both the physician and the patient. Selecting the right therapy from the beginning should help minimize complications, reduce the number of hospitalizations, and may also help reduce the climbing incidence of bacterial resistance.

Update on Minocycline HCl SOLODYN™ Extended Release Tablets, Linezolid ZYVOX® 600mg, Tigecycline Tygacil®, and CF-1743.

Management of the patients’ expectations and compliance are crucial aspects of acne treatment. Disease chronicity and long-term treatment should be discussed at length during the initial consultation.

Update on

Educate and counsel. Most patients with acne are teenagers who are very self-conscious about their looks and expect immediate treatment results. However, adult acne is becoming more common, and can be very distressing as well.

Since multiple factors are involved in the pathophysiology of acne, treatment that counteracts the majority of them can be expected to achieve the best results. When considering the options for reducing the P. acnes population, it is best to choose those that do not encourage resistance patterns.

Wound care after laser skin resurfacing is critical for achieving a successful result. The superficial thermal injury created by laser skin resurfacing heals more quickly and with a reduced risk of scarring under occlusion. Effective management techniques can help minimize expected negative effects.

Oral isotretinoin, since its introduction more than 20 years ago, has been and still is the 'gold standard' in the treatment of acne and its variants. This is the only approach to acne with the possibility of a permanent “cure” or long term remission.

With so many new peel preparations on the market today, the dermatologist must ask himself basic questions concerning the products. The most important question is directed to the medical literature rather than the advertising or marketing campaign so common among marketdriven cosmetic products.

There is compelling evidence that oral contraceptives (OCs) are effective in the management of mild-moderate acne vulgaris, as well as cumulative evidence that elevated levels of androgens in acne patients, relative to appropriate controls, are an underlying pathophysiological factor in acne.

Vulvovaginal candidiasis is a common occurrence among women over 25 years of age. The likelihood of developing infection increases with pregnancy, the use of oral contraceptives or antibiotics, or immune disorders. However, in many cases, the etiology of the disorder is unknown.

Allergic contact dermatitis (ACD) is more frequent in the pediatric population and in children with atopic dermatitis (AD) than has hitherto been appreciated. Patch testing, which is mediated by different immune mechanisms than prick skin testing, is both safe and diagnostically useful for individuals with AD.

Acne is a multifactorial disease of the pilosebaceous unit in the skin. Four contributing pathogenic factors need to be elucidated and include excess sebum production, follicular hyperkeratinization, colonization of the pilosebaceous unit by Propionibacterium acnes.

Psoriasis, acne vulgaris and photoaging are common conditions. Tazarotene is a pro-drug of tazarotenic acid, a receptor-selective retinoid, which has shown efficacy in the treatment of these disorders. In the treatment of acne vulgaris, it has greater comedolytic activity than the currently available topical retinoids.

Bullous pemphigoid (BP) is the most frequently occurring autoimmune blistering disease in Europe and North America. Although it is primarily a disease of the elderly, children and young adults can also develop it.

Rosacea is relatively common, typically occurring in individuals of Northern European and Celtic origin between 30 and 50 years of age. It is more common in women, but may be more severe in men. Currently there is no cure available for rosacea, but it can be controlled with topical and oral drug therapy.

Update on: Etanercept Enbrel® Clindamycin 1%, Benzoyl Peroxide 5% BenzaClin™ Ethinylestradiol & Norethindrone Acetate Estrostep Desloratadine Aerius™ & Neoclarityn™ Agalsidase Alfa Replagal™ Ciprofloxacin Butenafine HCl Mentax®

Chronic palmoplantar pustular psoriasis is a disabling condition characterized by recurrent crops of sterile pustules on a background of erythema, fissuring and scaling. Genetic and environmental factors have been implicated in its etiology.

Oral contraceptives (OCs) can reduce acne by lowering the production of adrenal and ovarian androgens, by inhibiting 5- alpha-reductase, which in turn, reduces the levels of dihydrotestosterone, and by stimulating sex hormone binding globulin (SHBG), thus reducing the levels of free testosterone.

Updates on: 5-fluorouracil 5-FU Microsponge Interferon-Alpha Veldona Hydroxyurea Amprenavir Agenerase Diclofenac Sodium Solaraze

Treatment objectives and pharmacoeconomic considerations are important when developing guidelines that are effective and rational. Canadian Acne Treatment Guidelines were last published in 1995. New guidelines were recently developed to incorporate therapeutic advances and data from more recent studies.

Diane-35®, known as Dianette® in some countries, is a combination of cyproterone acetate 2 mg and ethinyl estradiol 0.035 mg. It has recently received regulatory clearance in Canada, but has not yet been approved by the US FDA.

Clinical rosacea is not a single disease but rather a combination of cutaneous stigmata which include flushing, erythema, telangiectasia, facial edema, papules, pustules, ocular lesions, and rhinophyma. A review of rosacea, treatment, and management.

Antibiotic prophylaxis aims to prevent wound infections and provide adequate antibiotic cover for patients with prostheses or at risk for endocarditis. Most recommendations are based spread of risk factors may not accurately predict the risks for patients. A case for prophylaxis is made.

Benzoyl peroxide 5% plus erythromycin 3% (Benzamycin. gel, Dermik) will be evaluated. Although it is not known how effective it is compared with benzoyl peroxide and erythromycin prescribed separately, Benzamycin® is simpler to use and likely to improve patient compliance.